%20(1).avif)
.avif)
Metabolic Health Starts in the
Portal-Hepatic Region
The portal-hepatic region is the body’s metabolic control center, integrating signals from insulin, GLP-1, and serotonin as they travel the portal-hepatic circulation. Together, these hormones regulate glucose and fat metabolism, nutrient storage, and appetite—linking the gut, liver, and brain in the physiologic control of energy balance.
Why Hepatocytes Matter
Hepatocytes are the liver’s functional core—utilizing and clearing insulin, GLP-1, and serotonin as they enter the liver through the portal vein. These specialized cells regulate how the body stores nutrients and controls whole-body blood glucose and fat metabolism. Today’s therapies struggle to reach hepatocytes and instead act in peripheral tissues. This divergence from natural physiology contributes to diminished efficacy, greater side effects, and limited durability.
Hepatocyte-Directed Vesicle (HDV™) Platform
HDV enables access to the mechanism-rich portal-hepatic region, shifting drug action from
peripheral tissues to the liver, the control center of metabolism.
Advancing Next-Generation Therapies
HDV is a first-in-class platform that delivers drug actives to the portal-hepatic region with precision. HDV is safe and compatible with a wide range of active pharmaceutical ingredients. HDV offers a scalable and differentiated approach to developing the next generation of metabolic therapies.
Redefining What We Know About Hypoglycemia
OPTI-2 Phase 2b trial data demonstrate that targeting HDV-Insulin to the liver maintains glycemic control while reducing hypoglycemia, providing the first clinical evidence that tighter control and lower risk can coexist.
Advancing breakthrough therapies
Diasome’s pipeline is advancing therapies across three key areas:
Insulin
Reducing the daily burden of hypoglycemia for patients on mealtime insulin.
GLP-1
Activating the liver-gut-brain axis for improved incretin therapy.
Serotonin
Addressing insulin resistance in Type 2 diabetes.
A portfolio focused on unmet needs in
diabetes, obesity, and other cardiometabolic diseases
HDV-Insulin OPTI-2 phase 2b trial results: Equivalent glycemic control with less hypoglycemia
- A1C non-inferiority maintained
- Statistically significant reductions in hypoglycemia
- Dramatic reduction in severe hypoglycemic events with HDV-insulin
- New insight into hypoglycemia burden
Committed to Breakthroughs. Focused on Outcomes.
Diasome is led by world-renowned researchers, clinicians, and biotech experts dedicated to advancing metabolic therapies.
Since our founding, we have worked tirelessly to bridge the gap between scientific discovery and real-world patient impact.
.avif)